drugset / Trial / NCT02826837
LEAC-102 for Advanced Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-02-01
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LEAC-102 | Unknown | 1500 mg | Oral |
| Subject | LEAC-102 | Unknown | 2000 mg | Oral |
| Subject | LEAC-102 | Unknown | 2500 mg | Oral |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |